Compare DexCom, Inc. (DXCM) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? DexCom, Inc. trades at $83.83 (market cap $31.86B), while Direxion Daily Semiconductor Bear 3X Shares trades at $34.48 (market cap $1.96B). The key difference: DexCom, Inc. is far larger — about 16.3× Direxion Daily Semiconductor Bear 3X Shares's market cap, and DexCom, Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| DXCM | SOXS | |
|---|---|---|
Market Cap | $31.86B | $1.96B |
Volume | 3,607,070 | 113,512,541 |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.34 | $988.00 |
52-Week Low | $54.84 | $29.62 |
Typical Hold Time | 62 Days | 11 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
SOXS, a leveraged inverse ETF tracking the semiconductor sector, trades at $34.12, up 11.34% over 24 hours amid recent semiconductor stock weakness. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. The fund executed a 1:10 stock split in July 2026 and has a dividend scheduled for September 2026. News highlights focus on volatility and tactical use, with articles noting surges during chip sell-offs.
The outlook for SOXS remains highly speculative, suitable only for short-term tactical trades due to its leveraged inverse structure and extreme volatility. Key risks include rapid erosion from semiconductor sector rebounds and structural decay. Investors should avoid long-term holdings, as persistent AI demand could trigger sharp losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
